The slippery slope of the human gene editing debate
By John Evans,
Oxford University Press Blog
| 09. 22. 2020
The ethical debate about what is now called “human gene editing” (HGE) began sixty years ago. At the time, eugenicist scientists wanted to use new knowledge about the structure of DNA to modify humans—to perfect the human species by making us more healthy, musical, intelligent, and generally virtuous. A consensus later formed that gene editing on individuals to remove disease is acceptable, but nobody should try to change the human species. This is known as the somatic (individual) vs. germline (species) distinction, and it served as a moral limit on HGE for 50 years. A few years ago the news broke that a Chinese scientist had facilitated the creation of children who have been genetically modified so their descendants would also be modified—germline HGE. The germline limit now seems to be gone. Are there any limits left?
The HGE debate, like many bioethical debates, is set up like a slippery slope. At the top is an act universally considered morally virtuous (point A). Stepping on the slope at the top makes the act a little bit further down the slope...
Related Articles
By Ian Sample, The Guardian | 07.04.2024
Biological models of human embryos that can develop heartbeats, spinal cords and other distinctive features will be governed by a code of practice in Britain to ensure that researchers work on them responsibly.
Made from stem cells, they mimic, to...
By Kevin Davies, Genetic Engineering & Biotechnology News | 06.27.2024
Physician-scientist Matthew Porteus, MD, PhD, has been a mainstay in the genome editing field for more than two decades. He trained at Stanford University Medical School before completing his residency and hematology/oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...